Tumor targeting drug-loaded particles

Details Tumor targeting drug-loaded particles Tumor targeting drug-loaded particles

2005-10-03

2011-10-25

Fetterolf, Brandon (Department: 1628)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S457000, C514S034000, C514S449000, C514S456000

Reexamination Certificate

active

08043631

ABSTRACT:
A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing agent in a pharmaceutically acceptable carrier may be administered before or concomitantly therewith. Nanoparticles or microparticles (e.g., cross-linked gelatin) of the therapeutic agent (e.g., paclitaxel) also may be used. The nanoparticles or microparticles may be coated with a bioadhesive coating. Microspheres that agglomerate to block the entrance of the lymphatic ducts of the bladder to retard clearance of the microparticles through the lymphatic system also may be employed. This invention also uses drug-loaded gelatin and poly(lactide-co-glycolide) (PLGA) nanoparticles and microparticles to target drug delivery to tumors in the peritoneal cavity, bladder tissues, and kidneys.

REFERENCES:
patent: 5702717 (1997-12-01), Cha et al.
patent: 6287285 (2001-09-01), Michal et al.
patent: 6506405 (2003-01-01), Desai et al.
patent: 6881420 (2005-04-01), Flashner-Barak et al.
patent: 2004/0247624 (2004-12-01), Unger et al.
patent: WO 0061141 (2000-10-01), None
Signore et al. J. Vasc. Interv. Radiol. 200112:79-87.
Alakhov et al, Exp. Opin. Biol. Ther. 2001 1(4):583:602.
Jessie et al. Cancer research 58 2141-2148 1998.
www.mesotheliomaweb.org/categories.htm 5 pages 199867.
J. of Controlled release V 86 (2003) 33-48 is of interest.
New drugs of 1999 Medscape Today, 1999, 1-14.
Jae-Woon Korean J. Chem. Eng 17 (2000): 230-236.
Fonseca et al. (J. Controlled Release 83 (2002) 273-286).
Mu et al. (J. Controlled Release 86 (2003) 33-48).
Falcone, A, Pfanner, E. Brunetti, I, et al., Suramin in Combination with 5-Flurorouracilacil (5-FU) and Leucovorin (LV) in Metastatic Colorectal Cancer Patients Resistant to 5-Fu+LV-Based Chemotherapy, Tumori, vol. 84: pp. 666-668, yr 1988.
Armstrong, DK, Fleming, GF, Markman, M et al., A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol., yr 2006, pp. 391-396, vol. 103.
Chen, D, Song, D, Wientjes, MG et al., Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin. Cancer Res., yr 2003, pp. 363-369, vol. 9.
Demetrick, JS, Liggins, RT, Machan, L et al., The development of a novel intraperitoneal tumor-seeding prophylactic. Am. J. Surg., yr 1997, pp. 403-406, vol. 173.
Ensminger, WD, and Gyves, JW, Regional chemotherapy of neoplastic diseases. Pharmacol. Ther., yr 1983, pp. 277-293, vol. 21.
Harper, E, Dang, W, Lapidus, RG et al., Enhanced efficacy of a novel controlled release paclitaxel formulation (Paclimer delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin. Cancer Res., yr 1999, pp. 4242-4248, vol. 5.
Kiguchi, K, Kubota, T, Aoki, D et al., A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer. Clin. Exp. Metastasis, yr 1998, pp. 751-756, vol. 16.
Machida, Y, Onishi, H, Kurita, A et al., Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats. J. Control Release, yr 2000, pp. 159-175, vol. 66.
Markman, M, Rowinsky, E, Hakes, T et al., Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J. Clin. Oncol., yr 1992, pp. 1485-1491, vol. 10.
Rasband, W. S. ImageJ. Http://Rsb.Info.Nih.Gov/lj/. 2008. NIH.
Tokuda, K, Natsugoe, S, Shimada, M et al., Design and testing of a new cisplatin form using a base material by combining poly-D,L-lactic acid and polyethylene glycol acid against peritoneal metastasis. Int. J. Cancer, yr 1998, pp. 709-712, vol. 76.
Tsai, M, Lu, Z, Wang, J et al., Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel. Pharm. Res, yr 2007, pp. 1691-1701, vol. 24.

Affiliated with

Also associated with

Rating

Tumor targeting drug-loaded particles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor targeting drug-loaded particles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor targeting drug-loaded particles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4276976